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Harmonized tuning of nucleic acid and lectin binding properties 
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b,
* and José M. García Fernández
b 
Polycationic amphiphilic cyclodextrins (paCDs) have been shown to behave as efficient non-viral gene carriers paralleling 
the efficacy of commercial vectors towards a variety of cell lines. Their molecular framework and modular design allow the 
installation of saccharidic antennae to promote specific carbohydrate-protein interactions, thus potentially endowing 
them with selective targeting abilities. Yet, the presence of these additional functionalities onto the polycationic cluster 
may hamper paCD self-assembly and nucleic acid condensation. In this report we describe the influence of paCD 
mannosylation extent on paCD-pDNA nanocomplex stability as well as the consequences of varying glycotope density on 
mannose-specific lectin recognition and gene delivery capabilites. The work aims at exploring the potential of this 
approach to optimize both properties in order to modulate cell transfection selectivity. 
1. Introduction 
Gene therapy (i.e. administering nucleic acid-based 
therapeutics to correct a particular cellular dysfunction) 
represents a promising alternative to conventional drugs due 
to the specific and predictable mode of action of 
polynucleotides.
1
 Yet, it faces the drawback of the poor drug-
likeness of nucleic acids, requiring purpose-conceived carriers, 
so-called vectors, to target their goal. Though their efficiency is 
still far from that of virus-based carriers, the advent of 
nanotechnology and the persisting safety concerns regarding 
the use of viral materials have fostered the design of a 
plethora of artificial gene vectors to cope with this task.
2
 
Molecular facial amphiphiles based on macrocyclic scaffolds,
3
 
among which polycationic amphipilic cyclodextrins (paCDs, 
Figure 1 left) are relevant representatives,
4,5
 have turned 
particularly promising in this regard. paCDs undergo nucleic 
acid-templated self-assembling affording supramolecular 
nanocomplexes (CDplexes) that promote transfection with 
efficiencies that rival that of formulations prepared with 
commercial polycationic polymer (polyplexes) or lipid vectors 
(lipoplexes), but with no or much milder toxicity. Selectivity is 
however similarly low, since cell uptake of CDplexes, as for 
polyplexes and lipoplexes, relies essentially in non-specific 
electrostatic interactions.
6
 Alternatively, exploiting specific 
ligand-receptor recognition events (e.g. between sugar 
epitopes and their complementary lectins) holds great promise 
for selectively targeting therapeutic genes.
7
 The concept was 
put forward nearly 20 years ago,
8
 but implementation with 
macromolecular systems is not that evident. Glycotargeting is 
presumed to arise from (i) the increase of the hydration shell 
of the carrier due to the hydrophilicity of the sugar motifs, 
which shields from non-specific (electrostatic) interactions, 
and (ii) specific receptor-mediated cell internalization (Figure 
1, right). Recently, we have demonstrated that installation of a 
homogeneous glycomultivalent display on the cationic domain 
of paCDs selectively promoted gene delivery to cells 
expressing complementary lectin receptors.
9
 Yet, the 
incorporation of glycoligands on the vector has a strong impact 
on the hydrophobic/hydrophilic balance and the 
hydrodynamic properties of the system, which may negatively 
affect self-assembling, nucleic acid compaction and, ultimately, 
transfections capabilities.
10,11
 Harmonizing glycotope and 
cationic group densities to warrant biologically useful affinities 
towards both the target lectin and the nucleic acid cargo is 
thus critical for those channels. 
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Figure 1. Schematic representation of the mechanisms involved in cell-
membrane binding of CDplexes: naked CDplexes (left) exploit non-specific 
electrostatic interactions with negatively-charged cell membrane proteoglycans. 
Conversely, in glycoCDplexes (right) these interactions are hampered by the 
heavier solvation of the carbohydrate shield, thus adhesion is mostly dependent 
on specific multivalent interactions with the appropriate receptor (lectin). 
In this paper, we report the synthesis of a series of statistically 
mannosylated paCDs featuring variable relative proportions of 
sugar and protonable amino centres and a preliminary 
assessment of how mannosylation extent modulates the 
nucleic acid condensing capacity, the dynamics and stability of 
the resulting glycoCDplexes, the binding affinity to mannose-
specific receptors and the transfection efficiency towards 
macrophage mannose receptor (MMR) positive (RAW 264.7) 
and negative (BNL-CL2 and COS-7) cell lines. 
2. Results and discussion 





 (Scheme 1), featuring very similar 
structures but subtle vector performance disparities, were 
selected as paCD scaffolds to investigate the effect of 
increasing mannosylation degrees on DNA complexing abilities 
and MMR recognition properties. The transfection efficiency of 
pDNA complexes formulated with triazol-armed paCD 1a is 
optimal at a nitrogen/phosphorus (N/P) ratio of 10.
13
 Thiourea-
tethered paCD 2a, on the other hand, achieves similar 
expression levels at a lower N/P (5), which is attributed to the 
privileged phosphate binding ability of the 2-
aminoethylthiourea segments on the cationic cluster.
12b
 




forming ligation chemistry (Scheme 1). Each individual 
coupling reaction results then in the replacement of a 
cationizable centre in the vector by a neutral biorecognizable 
glycotope. Reaction with increasing amounts of isothiocyanate 
3 (5 to 50% relative to the paCD primary amino groups), 
followed by purification by size exclusion chromatography, 
furnished two series of paCDs with different degrees of 
mannosylation (1b-e and 2b-e, respectively). ESI-MS and 
1
H 
NMR spectroscopy confirmed quantitative mannoside 






























compound % H % man
1b, 2b 95 5
1c, 2c 85 15
1d, 2d 70 30















































































Scheme 1. Synthesis of statistically mannosylated paCDs from 1a and 2a and structure 
of the homogenously mannosylated derivative 4 used as positive control in 
macrophage adhesion experiments. 
The above multiconjugation strategy provides a very 
convenient method to modulate the coating sugar content of 
the paCD vectors while significantly reducing the synthetic 
effort as compared with regioselective synthetic schemes 
previously implemented, e.g. for the synthesis of the 
heptamannosylated glyco(paCD) 4 (Scheme 1).
9
 Although it 
obviously affords polydisperse mixtures of statistically 
glycosylates adducts, it is presumed that differences in 
glycocluster topology at the molecular level would be blurred 
when considering the glycocoating corona in the 
nanocomplexes after self-assembling with pDNA.
7
 Indeed, the 
scenario is very similar to that encounter for statistic 
glycosylation of polymeric  or dendritic scaffolds, a routinely 
used strategy to generate multivalency.
10,15,16
 Glycotope 
density is then expected to become the main parameter 
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2.2. Self-assembling capabilities 
The influence of the mannosylation degree in the pDNA 
(luciferase-encoding pTG11236 plasmid) complexing 
capabilities of paCDs 1a-e and 2a-e was first screened by 
agarose gel electrophoresis migration experiments at different 
N/P ratios (1, 2, 5, and 10). No remarkable differences were 
noticed between the behaviour of triazol- (1a-e; Figure 2, left 
column) and thiourea-tethered (2a-e; Figure 2, right column) 
series. In general, mannosylation progressively decreases the 
ability to inhibit pDNA electrophoretic mobility of the paCDs, 
which is better evidenced in the thiourea-tethered series 
(Figure 2, right column). Nevertheless, regardless of their 
mannosylation degree, all glyco(paCDs) inhibited 
electrophoretic mobility of pDNA at N/P ratios above 2. 
Comparatively, the pDNA protection against the intercalating 
agent ethidium bromide is more influenced by mannosylation. 
While pDNA is already inaccessible to ethidium bromide at N/P 
≥2 in formulations with 1a and 2a (Figure 2, first row), N/P 5 
ratios are required for most mannosylated adducts to attain 
the same protection, mounting up to N/P 10 for the more 
heavily mannosylated triazol-linked glyco(paCD) 1e (50% 
mannosylation). Although electrostatic interactions with the 
plasmid are preserved, compaction is probably hampered as a 
consequence of the higher swelling capabilities imparted by 
the hydrophilic sugar residues. 
The hydrodynamic size and ζ-potential of glycoCDplexes 
formulated at N/P values 5 and 10 were next measured by 
dynamic light scattering (DLS) and mixed-mode measurement-
phase analysis light scattering (M3-PALS), respectively. 
Dispersion of paCDs in a solution of pDNA in water furnished 
single populations of rather homogenous nanoparticles 
(polydispersity index ≈ 0.2) in all cases. (Glyco)CDplexes 
obtained from triazol-containing paCDs 1a-e evidenced a 
gradual, though subtle, increase in size and a parallel decrease 
in ζ-potential upon increasing the mannosylation degree, 
which was especially noticeable for formulations at N/P 10 
(Figure 3, left). It is worth mentioning that although an 
increase in sugar valency is accompanied by a decrease in the 
number of protonable amino groups in the glyco(paCD) 
conjugates, this has been compensated by normalizing at the 
same N/P ratio. The observed trend is probably due to the 
increase in the thickness of the hydration shell with heavier 
mannosylation, which is also expected to shield the 
nanoparticle surface charge to some extent. The increase in 
size upon glycosylation was less evident in the thiourea-
tethered conjugates 2a-e (Figure 3, right). In this case, a 
significant decrease in ζ-potential was already observed for the 
vector with the lower glycosylation rate (2b, 5% 
mannosylation), further increases in valency having much 
more modest consequences. It is hypothesized that the higher 
flexibility of the linker in this series allows a better 
accommodation of the mannosyl residues in the 
glycoCDplexes, minimizing the impact of glycosylation density 
variations. 
 
Figure 2. pDNA retardation in agarose gel vs mannosylation degree (from top to 
bottom, 0 to 50% of available primary amino groups, respectively) and N/P ratio (0 to 
10, lanes 1 to 5 in each picture). Left and right columns collect data for paCD 1a-e and 
2a-e, respectively. 
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Figure 3. ζ-Potential (A) and hydrodynamic diameter (B) of statistically mannosylated 
CDplexes formulated at N/P 5 (white circles and empty bars) and 10 (filled squares and 
dotted bars) determined by M3-PALS and DLS, respectively. 
The effect of mannosylation extent on the size and stability of 
the nanocomplexes formulated with the paCD derivatives 1a-e 
and 2a-e and pDNA in saline medium (up to 150 mM NaCl) was 
next investigated to further assess their behavior under 
physiological conditions. As a general trend, mannosylation 
attenuated the effect of saline stress on the colloidal stability 
of glycoCDplexes, as seen from the less pronounced 
differences in size (Supplementary Information, Fig. S11). This 
result is in agreement with previous reports on glycocluster-
based vectors
10,17
 and reinforces the notion that sugar coating 
prevents non-specific aggregation phenomena, probably by 
endowing the nanoparticles with a thicker hydration shell. The 
accessibility of ethidium bromide to the pDNA cargo in the 
most heavily mannosylated glycoCDplexes (e.g. 1e) increases 
under saline stress (Supplementary Information, Fig. S12), also 
pointing to a non-optimal hydrophilic/hydrophobic balance at 
such high mannose coating densities. 
 
2.3. Alveolar macrophage adhesion 
The average mannose valencies of the paCDs prepared and 
evaluated in this work, taken as individual entities, are 0, 0.7, 
2.1, 4.2 and 7 for 1a and 2a to 1e and 2e, respectively. 
According to results reported for non-amphiphlic CD-
scaffolded glycoclusters,
18
 a significant multivalent effect 
would be expected only for the later derivatives. Yet, after 
supramolecular self-assembling in the presence of pDNA a 
hyper-valent display of mannosyl epitopes will be generated at 
the surface of the glycoCDplexes formulated with 1b-e and 2b-
e. We were particularly interested at investigating the 
minimum mannosylation rate leading to functional DNA 
nanocomplexes capable of eliciting a biologically significant 
binding to cells expressing the macrophage mannose receptor. 
For such purpose, glycoCDplexes were formulated using pDNA 
labelled with the fluorescent probe YOYO-1 at N/P ratios 5 and 
10. The ability of these particles to adhere the surface of 
alveolar peritoneal macrophages at 4 ºC (to prevent 
endocytosis) was assessed by fluorescence intensity 
measurements (Figure 4).
19
 At the lower N/P ratio, a significant 
increase in fluorescence was noticed even at relatively low 
mannosylation ratios as compared to negative controls (naked 
pDNA, non-glycosylated CDplexes formulated with paCDs 1a 
and 2a, and polyplexes formulated with the commercial vector 
JetPEI).
20
 Interestingly, fluorescence intensity plateaued at ca. 
15-30% mannosylation (1c, 2c and 1d, 2d), with residual 
increase at higher glycan ratios. Indeed, similar macrophage 
adhesion levels were obtained for the positive control, the 
homogeneously 50% mannosylated paCD 4 (Scheme 1). At N/P 
10, though the tendency is similar, the contrast is lower, due 
to the higher background of non-specific electrostatic 
interactions. As it could be expected, the higher the cationic 
content, the lower the contribution of specific interactions to 
the overall adhesion process, a phenomenon already 




Figure 4. Adhesion to alveolar peritoneal macrophages (mice) of statistically 
mannosylated CDplexes 1a-e and 2a-e formulated at N/P ratio 5 (white bars) and 
10 (grey bars) vs. naked pDNA. JetPEI polyplexes and 4:pDNA CDplexes 
formulated at the same N/P ratio were used as negative and positive controls, 
respectively. 
To confirm the specificity of the interactions at play, the above 
experiments were run in the presence of native and 
mannosylated-BSA (Man-BSA) as competing agents, using the 
optimal N/P ratio 5. A mannose concentration-dependent 
inhibition of glycoCDplex adhesion to the macrophages was 
observed for the later, with fluorescence intensity values 
reduced to basal levels in the presence of 1 mg·mL
-1
 of Man-
BSA (Figure 5). On the other hand, native BSA minimally 
affected adhesion. Neither BSA nor Man-BSA significantly 
affected the adhesion of JetPEI polyplexes and non-
mannosylated CDplexes to macrophages, altogether strongly 
supporting the involvement of specific mannose-MMR 
recognition in the adhesion of the glycoCDplexes formulated 
with 1b-e and 2b-e to the macrophages.  
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Figure 5. Adhesion of CDplexes 1a-e (A) and 2a-e (B) formulated at N/P 5 in the 
absence of BSA (white bars), in the presence of mannosylated-BSA (0.1 and 1 mg·mL
-1
, 
dotted and slashed bars, respectively) or in the presence of native BSA (grey bars). 
JetPEI polyplexes and 4:pDNA CDplexes formulated at the same N/P ratio were used as 
negative and positive controls, respectively. 
2.4. Cell transfection 
CDplexes formulated at N/P 5 with luciferase-encoding pDNA 
(pTG11236) and the multivalent paCD vectors having 15 and 
30% of the primary amino groups replaced by mannosyl 
antennae (1c, 2c and 1d, 2d, respectively) were selected for 
cell transfection assays. According to the previously discussed 
results, these formulations exhibit the best balance between 
pDNA protection, colloidal stability and MMR-binding 
efficiency, which was expected to maximize receptor-mediated 
versus non-specific (electrostatic-mediated) cell uptake. 
Transfection was monitored in MMR-positive mouse 
leukaemic monocyte macrophages (RAW 264.7) and in MMR-
devoid embryonic murine hepatocytes (BNL-CL2) and African 
green monkey kidney fibroblasts (COS-7). In all three cell lines 
and for all formulation, cell viabilities were determined to be 
above 80%. The corresponding luciferase expression data are 
plotted in Figure 6. Naked pDNA and JetPEI polyplexes 
formulated at N/P 5 were used as negative and positive 
controls, respectively (see Supplementary Information for 
experimental details).  
The graphs depict two different scenarios depending on the 
presence of triazol (1a, 1c and 1d) or thiourea linkers (2a, 2c 
and 2d). In the triazol-tethered series, the transfection 
efficiency of the non-mannosylated CDplexes formulated with 
paCD 1a at N/P 5 is very poor in the three cell lines, only 
marginally improving that of naked pDNA. Indeed, previous 
results have shown that triazol-tethered paCD efficiency peaks 
at higher N/P ratios, ca. 10.
13
 The mannosylated vectors 1c and 
1d behaved similarly poorly in the MMR-devoid BNL-CL2 and 
COS-7 cell lines (Figure 6A). Rewardingly a significant 
enhancement of the transfection efficiency relative to the 
control was observed in MMR-expressing RAW264.7 cells (29- 
and 12-folds for glycoCDplexes formulated with 1c and 1d, 
respectively). A direct comparison of the data for the three cell 
lines reveals a 5 to 12-fold higher protein expression in MMR-
expressing as compared to MMR-devoid cells (Figure 7A). 
 
Figure 6. Transfection efficiency in terms of luciferase expression in BNL-CL2, 
COS-7, and RAW 264.7 cells for CDplexes formulated at N/P 5 with triazol-
tethered (1a, grey bars; 1c, dotted bars; 1d, slashed bars; panel A) and thiourea-
tethered (2a, grey bars; 2c, dotted bars; 2d, slashed bars; panel B) paCDs. Naked 
pDNA was used as negative control. 
CDplexes formulated with the thiourea-tethered paCD 2a at 
N/P 5 already elicited relevant levels of luciferase activity in all 
three cell lines. Upon conjugation with mannose, transfection 
levels dropped very significantly in MMR-devoid BNL-CL2 and 
COS-7 cells (Figure 6B). In contrast, transfection of RAW264.7 
macrophages with the mannosylated conjugates 2c and 2d 
remained unaltered, probably because the detrimental effect 
due to attenuation of electrostatic interactions is compensated 
by activation of MMR-mediated cell uptake mechanisms. Even 
though a net enhancement in macrophage transfection 
efficiency is not achieved, off-target effects are very 
significantly reduced, imparting cell selectivity. Thus, while the 
parent paCD vector 2a promoted transfection of the 
hepatocyte and fibroblast cells with 13- and 100-fold higher 
efficiencies as compared with macrophages, the corresponding 
conjugate 2c, with a 15% mannose incorporation, transfected 
preferentially macrophages, with 31-fold and 16-fold higher 
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efficiency as compared with hepatocytes and fibroblasts, 
respectively (Figure 7B). This means a reversion of the cell 
selectivity in favour of the MMR-expressing cells by a factor of 
400 to 1600. 
 
Figure 7. Normalized transfection efficiency of CDplexes formulated at N/P 5 
with triazol-tethered (1a, 1c and 1d; A) and thiourea-tethered (2a, 2c and 2d; B) 
paCDs in BNL-CL2 (white bars), COS-7 (dotted bars), and RAW 264.7 (slashed 
bars) cells. Luciferase expression levels in BNL-CL2 cells have been arbitrarily 
given the value 1, so that the values for COS-7 and RAW 264.7 cells represent 
transfection potency (in folds) relative to the former. 
4. Conclusions 
The results presented in this work demonstrate that the 
installation of defined proportions of saccharidic epitopes onto 
molecular polycationic amphiphilic CD scaffolds can be used to 
modulate their DNA-templated self-assembling capabilities 
and the functional properties of the resulting nanocomplexes. 
Self-assembling of glyco(paCDs) leads to amplification of 
interactions with complementary lectin receptors by 
generating a multivalent glyocodisplay at the nanoparticles 
surface. Glycocoating additionally shields the positive charge 
of glycoCDplexes, decreasing the non-specific electrostatic 
interactions with proteoglycans at the cell surface. Altogether 
glyco(paCDs) can be exploited to enhance cell transfection 
selectivities by judiciously tuning the nucleic acid and lectin 
binding properties, as exemplified here for macrophages, after 
synchronized adjustment of the positive charge density and 
the glycosylation extent. 
5. Experimental 
5.1. General methods 
Reagents and solvents were purchased from commercial 
sources and used without further purification. NMR spectra 
were recorded at 500 MHz. 2D COSY, 1D TOCSY experiments 
were used to assist on NMR assignments. Gel permeation 
chromatography was carried out on Sephadex G-25 (GE 
Healthcare Life Sciences). Electrospray mass spectra (ESIMS) 













Procedure for statistical mannosylation of paCDs 1a and 2a: To 
a solution of paCD (12 μmol) and Et3N (47 μL, 0.34 mmol, 2 eq) 
in dry DMF (5 mL), a solution of 2-isothiocyanatoethyl α-D-
mannopyranoside 3 (2.2 mg, 6.7 mg, 13.3 mg or 22.3 mg for 
0.05, 0.15, 0.30 or 0.50 eq per primary amino group, 
respectively) in DMF (5 mL) was added and the solution was 
stirred overnight at room temperature. The solvent was 
removed under vacuum and the residue was purified by size 
exclusion chromatography (Sephadex G-25) using water as 
eluent. The purified compound was dissolved in diluted HCl 0.1 
N and freeze-dried to give a white foam in nearly quantitative 
yields. For detailed characterization see Supplementary 
Information section. 
 





employed for the preparation of the DNA complexes and for 
transfection assay is a plasmid of 5739 bp (base pairs). The 
quantities of each formulation were calculated according to 
the DNA concentration (0.1 mg·mL
-1
, 303 μM phosphate), the 
N/P ratio, the molar weight and the number of positive 
charges in the paCD derivative or cationic polymer (JetPEI®).
20
 
Experiments were performed for N/P 1, 2, 5 and 10. 
Concerning the preparation of the DNA complexes from paCD 
derivatives and JetPEI, pDNA was diluted in HEPES (20 mM, pH 
7.4) to a final concentration of 303 μM (1 mg·mL
-1
), then the 
desired amount of CD derivative was added from a 20 mg·mL
-1
 
stock solution (DMSO-water, 1:2, v:v) and JetPEI  was added 
from a 0.1 M stock solution (water). Final concentration of 
DMSO never exceeded 2% in these preparations. The 
preparation was vortexed for 2 h and used for characterization 
or transfection experiments. 
 
5.4. Agarose gel electrophoresis  
Each CD derivative/DNA sample (20 µL, 0.4 µg of plasmid) was 
electrophoresed for about  30 min under 150 V through a 0.8% 
agarose gel in TAE 1X (Tris-acetate-EDTA) buffer and stained by 
spreading an ethidium bromide (Sigma) solution in TAE buffer 
(20 μL ethidium bromide of a 10 mg·mL
-1
 solution in 200 mL 
TAE). The DNA was then visualized after photographing on an 
UV transilluminator.  
 
5.5. Particle size and ζ potential measurements 
The hydrodynamic diameters of the vesicles formed from the 
paCDs were measured by Dynamic Light Scattering (DLS) at 
633 nm on a Nanosizer S DLS instrument (Malvern 
Instruments) at 25 ºC and at a detection angle of 173º. All the 
measurements were performed in triplicate. Data were 
analysed using the multimodal number distribution software 
included in the instrument. Results are given as volume 
distribution of the major population by the mean diameter 
with its standard deviation. Statistical analysis of the particle 
size was performed using a student’s test (with two-sample 
unequal variance and two distribution tails). The ζ potential 
measurements were also performed in the same instrument 
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using 'Mixed Mode Measurement' phase analysis light 
scattering (M3-PALS). M3 consists of both slow field reversal 
and fast field reversal measurements, hence the name 'Mixed 
Mode Measurement' that improves accuracy and resolution. 
PALS is a variation of laser Doppler velocimetry that uses the 
phase shift (i.e. frequency x time) instead of the frequency 
shift to determine electrophoretic mobilities and hence 
convert them into zeta potentials. The following specifications 
were applied: sampling time, automatic; number of 
measurements, 3 per sample; medium viscosity, 1.054 cP; 
medium dielectric constant, 80; temperature, 25 °C; beam 
mode F(Ka) ) 1.5 (Smoluchowsky). Experiments were run by in 
triplicate. 
 
5.6. Salt-induced CDplex dissociation assays 
CDplexes were prepared as described above in order to obtain 
a final DNA concentration of 60 µM after adding a volume 
(representing 10% of total volume) of a NaCl solution in HEPES 
(in order to obtain a final NaCl concentration of 0, 50, 150 and 
250 mM), and a volume (representing 2% of total volume) of a 
100 µM ethidium bromide solution in DMSO. After adding, 
each preparation was vortexed for 15 minutes before 
fluorescence measurements. Each CDplex formulation was 
arrayed in triplicate into a white flat-bottom 96-well plate. The 
ethidium bromide fluorescence of each sample was measured 
with a luminometer (GENIOS PRO, Tecan France S.A.; 
excitation 485 nm, emission 590 nm). The relative ethidium 
bromide exclusion (% DNA excluded to ethidium bromide) was 
determined by the following relationship:  
Relative(EtBr exclusion) = 1 – [(Fsample – Fblank) / [FDNAonly – Fblank)] 
 
5.7. Alveolar macrophage adhesion assays 
For evaluation of the interaction of YOYO-1-labeled CDplexes 
with alveolar macrophages, the procedure reported by Muller 
and Schuber
19a
 for mannosylated liposomes was adapted. 
Briefly, resident peritoneal macrophages were obtained from 
female Balb/c mice (6 to 8 weeks old) and maintained in 
Dulbecco’s modified Eagle’s medium (DMEM; Gibco-BRL) 
supplemented with 10% decomplemented fetal calf serum 





 and the suspension was platted (final 
volume 1 mL) in multi-well plates. After 2 h in a humidified 
atmosphere of 5% CO2 in air (final pH 7.4), non-adherent cells 
were eliminated by rinsing the dishes three times with PBS. 
The adherent cells, 24 h after their isolation, were fed with 
fresh serum-less DMEM and incubated with CD-pDNA 
nanocomplexes, PEI polyplexes and naked DNA (control) at 
similar DNA concentration used in transfection assays. After 
the incubation time, the medium was pipetted-off and the 
cells washed four times with cold PBS (4 ºC). The fluorescent 
tag associated to the cells was measured fluorimetrically 
(Perkin Elmer luminescence spectrometer LS50B, excitation at 
491 nm and monitoring emission at 509 nm) after cell 
digestion in 1 mL PBS containing 0.1% of emulphogene BC-720, 
and scraping with a rubber policeman. Experiments were run 
in duplicate, and results did not differ more than 10%. 
 
5.8. In vitro transfection 
Twenty-four hours before transfection, BNL-CL2, COS-7, and 
RAW264.7 cells were grown at a density of 2 x 10
4
 cells/well in 
a 96-well plates in Dulbelco modified Eagle culture medium 
(DMEM; Gibco-BRL) containing 10% foetal calf serum (FCS; 
Sigma) in a wet (37 ºC) and 5% CO2/95% air atmosphere. The 
complexes CD derivative/DNA or PEI/DNA polyplexes were 
diluted to 100 μL in DMEM in order to have 0.5 μg of DNA in 
the preparation. The culture medium was removed and 
replaced by these 100 μL of complexes in DMEM. After 4 h and 
24 h, 50 and 100 μL of DMEM supplemented with 30% and 
10% FCS, respectively, were added. After 48 h, the transfection 
was stopped, the culture medium was discarded, and the cells 
washed twice with 100 μL of PBS and lysed with 50 μL of lysis 
buffer (Promega, Charbonnières, France). The lysates were 
frozen at -32 ºC, before the analysis of luciferase activity. This 
measurement was performed in a LB96P luminometer 
(BERTHOLD, France) in dynamic mode, for 10 s on 10 mL on 
the lysis mixture and using the “luciferase” determination 
system (Promega) in 96-well plates. The total protein 
concentration per well was determined by the BCA test 
(Pierce, MontluÇon, France). Luciferase activity was calculated 
as femtograms (fg) of luciferase per mg of protein. The 
percentage of cell viability of the nanocomplexes was 
calculated as the ratio of the total protein amount per well of 
the transfected cells relative to that measured for untreated 
cells x 100%. 
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